Updated:
Relay Therapeutics
Relay Therapeutics uses its Dynamo platform to drug previously intractable targets in precision oncology and genetic disease.
Relay Therapeutics
Relay Therapeutics operates as a drug-discovery company headquartered in Cambridge, Massachusetts. It was founded to integrate leading-edge experimental and computational approaches into a unified platform, a structural departure from traditional pharmaceutical R&D. The firm's Dynamo platform aims to visualize protein motion in high definition, enabling drug design against targets that have resisted conventional small-molecule approaches. Relay's pipeline concentrates on precision oncology and genetic disease, with an initial focus across these areas. The company maintains a single office location at 60 Hampshire Street and conducts all research and development from that site. Team size and AUM are not publicly disclosed. The firm employs a staff to run its platform and pipeline, but no specific professional count is available. No recent operational event within the last 24 months has been publicly reported. Relay Therapeutics operates as a single-site biotechnology company, with no separate investment vehicles or disclosed philanthropic structures. Its structural differentiator is the focus on protein motion—a biophysical property—as the core of its drug discovery engine, rather than relying on static structural biology alone.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Relay Therapeutics?
Relay Therapeutics does not publicly disclose a named investment committee or lead. As a drug-discovery company rather than a family office or investment fund, its capital allocation decisions are made by its board of directors and executive leadership, which is not publicly detailed.
Is Relay Therapeutics structured as a single family office or does it operate more like a venture firm?
Relay Therapeutics operates as a biotechnology company, not a family office or venture firm. Its legal and operational structure is that of a Delaware corporation focused on drug research and development, with no disclosed investment vehicles or external LP commitments.
Does Relay Therapeutics participate in fund commitments or only direct deals?
Relay Therapeutics does not disclose any fund commitments. Its activities are entirely direct: it conducts internal R&D and advances its own pipeline of therapeutic candidates. No external limited-partner relationships have been publicly identified.
Which sectors does Relay Therapeutics explicitly avoid?
Relay Therapeutics has not publicly stated any sectors it avoids. Its known focus is precision oncology and genetic disease, which implies it does not pursue broad therapeutic areas such as infectious disease, neurology, or cardiovascular medicine.
What investment stages does Relay Therapeutics typically target?
Relay Therapeutics does not target investment stages; it advances its own drug candidates from discovery through clinical development. Its pipeline includes preclinical and clinical-stage programs, but the firm itself is not an investor in external companies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: